Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (60)

III-01Noha Abdelgawad

Population Pharmacokinetic Modeling of Linezolid in Plasma and Cerebrospinal Fluid in Adults with Tuberculous Meningitis (LASER-TBM Study)

Thursday 09:50-11:20

III-02Mahmoud Abdelwahab

Exposure-QTc modelling of Bedaquline, Clofazimine and Pretomanid in TB patients.

Thursday 09:50-11:20

III-03Fauke Assmus

Pharmacokinetic-pharmacodynamic analysis of DNDi-6148 in pre-clinical models of visceral leishmaniasis

Thursday 09:50-11:20

III-04Linda Aulin

The FAIR approach: Utilising a modelling and simulation workflow leveraging multisource data to support preclinical development and clinical trials

Thursday 09:50-11:20

III-05Salma Bahnasawy

A pharmacometric model on cytokine changes upon live Escherichia coli exposure in a porcine sepsis model

Thursday 09:50-11:20

III-06Enrique José Bandín Vilar

Correlation between trough concentrations and AUC of linezolid for sampling optimization in critically ill patients

Thursday 09:50-11:20

III-07Muhammad Bilal

Cefepime Population Pharmacokinetics and Target Attainment in Critically ill Patients with Estimation of Probability of Neurotoxicity

Thursday 09:50-11:20

III-08Davide Bindellini

Semi-mechanistic model-based analysis of plasma and target-site cefazolin pharmacokinetics and protein binding in obese and nonobese patients

Thursday 09:50-11:20

III-09Dong Woo Chae

Dynamical modeling of phage therapy using in vitro and in vivo preclinical data

Thursday 09:50-11:20

III-10Piyawat Chaivichacharn

Dose Reduction and Population Pharmacokinetics of Lopinavir/ritonavir with and without Rifampin in Thai HIV-infected patients

Thursday 09:50-11:20

III-11Vincent Chang

Stratified medicine approaches for the treatment of drug-susceptible tuberculosis: a novel phase 2 trial design

Thursday 09:50-11:20

III-12Lu Chen

An integrated population pharmacokinetic analysis for posaconazole oral suspension, delayed-release tablet, and intravenous infusion in healthy volunteers

Thursday 09:50-11:20

III-13Wendy Chu

Semi-mechanistic PK modelling of drug-macrophage interactions affecting the disposition of liposomal amphotericin B in plasma and skin tissue of post kala-azar dermal leishmaniasis patients

Thursday 09:50-11:20

III-14giovanni Di Veroli

Bone Remodeling QSP to Guide Clinical Trial Design of WNT pathway inhibitors

Thursday 09:50-11:20

III-15Selma El Messaoudi

A semi-mechanistic model to characterize the long-term dynamic of HBV markers during treatment with lamivudine and PEG-IFNa

Thursday 09:50-11:20

III-16Omar Elkayal

A patient-level population pharmacokinetics meta-analysis of three posaconazole formulations in immunocompromised paediatric patients

Thursday 09:50-11:20

III-17Sandra Grañana Castillo

Physiologically based pharmacokinetic (PBPK) modelling of drug-drug interactions between long-acting cabotegravir and rilpivirine with oral rifabutin

Thursday 09:50-11:20

III-18Silvia Grandoni

Antitubercular effects of TBAJ-587 a new diarylquinoline derivative on sub-populations of M. tuberculosis and prediction of early bactericidal activity in humans

Thursday 09:50-11:20

III-19Yuchen Guo

Modeling spatial pharmacokinetics of drugs in mucus in patients with cystic fibrosis

Thursday 09:50-11:20

III-20Anubha Gupta

Characterisation of time course of response using model based meta-analysis of public domain data to support trial design in axial spondyloarthritis

Thursday 09:50-11:20

III-21Andrew Hooker

Model-based adaptive optimal design for nonlinear mixed-effects models with model structure uncertainty. Application in a simulated dose-finding study.

Thursday 09:50-11:20

III-22Sara Iannuzzi

Mathematical modelling of the molecular mechanisms of interaction of tenofovir with emtricitabine against HIV

Thursday 09:50-11:20

III-23Anouk Jansen

Population pharmacokinetics of itraconazole and hydroxy-itraconazole following administration of an intravenous nanocrystal formulation

Thursday 09:50-11:20

III-24Alexander Janssen

A Bayesian Optimization Procedure for the Automated Determination of Optimal Limited Sampling Strategies

Thursday 09:50-11:20

III-25Aida Kawuma

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF)

Thursday 09:50-11:20

III-26Charlotte Kern

Development of a priori dosing nomograms for daptomycin in patients at Swiss university hospitals

Thursday 09:50-11:20

III-27Christine Juliane Kleist

A PKPD model of ribavirin in Lassa virus infected mice

Thursday 09:50-11:20

III-28Simon Koele

Power to characterize exposure-response relations in phase IIa tuberculosis (TB) trials using bacterial load modeling

Thursday 09:50-11:20

III-29Daming Kong

A pooled pharmacokinetic analysis of piperacillin-tazobactam in different patient populations

Thursday 09:50-11:20

III-30Niklas Kroemer

A general pharmacodynamic interaction modelling approach to assess semi-mechanistic synergy of ceftazidime/avibactam and fosfomycin in time kill experiments

Thursday 09:50-11:20

III-31Max Lagraauw

Population Pharmacokinetic Analysis and Probability of Target Attainment Simulations of Pivmecillinam for the Treatment of Uncomplicated Urinary Tract Infection

Thursday 09:50-11:20

III-32Romain Leroux

Design evaluation and optimisation in nonlinear mixed effects models with the R package PFIM

Thursday 09:50-11:20

III-33Letao Li

Model informed precision dosing of meropenem in critically ill patients: mission impossible?

Thursday 09:50-11:20

III-34Guillaume Lingas

Modelling SARS-CoV-2 viral dynamics in hospitalized patients: implications for therapeutic evaluation

Thursday 09:50-11:20

III-35Claude Magnard

Optimizing the sample size of a bridging study using Simulx, an application of the MonolixSuite

Thursday 09:50-11:20

III-36Aurélien MARC

Characterization of SARS-CoV-2 variants of concern viral dynamics in non-human primates

Thursday 09:50-11:20

III-37Miao-Chan Huang

Population pharmacokinetics of amoxicillin in postpartum minipig plasma

Thursday 09:50-11:20

III-38Iris Minichmayr

Model-informed evaluation of prolonged versus short infusion regimens of meropenem based on two strategies of preclinical-clinical translation

Thursday 09:50-11:20

III-39Nele Mueller-Plock

Predicting RSV Efficacy for MK-1654 During Post-COVID-19 Pandemic RSV Seasons with Protracted Transmission Pattern using MBMA and Clinical Trial Simulation Approaches that Account for RSV Force-of-Infection

Thursday 09:50-11:20

III-40Glauco Nardotto

Population pharmacokinetics of rifampicin and 25-O-desacetyl-rifampicin in Brazilian patients with pulmonary tuberculosis living or not with HIV.

Thursday 09:50-11:20

III-41Thi Lien Ngo

Development of a physiological-based pharmacokinetic model for tegoprazan: its application to prediction of drug-drug interactions with clarithromycin

Thursday 09:50-11:20

III-42Amaury O'Jeanson

A simulation-based evaluation of the pharmacokinetic-pharmacodynamic (PK/PD) index approach for avibactam

Thursday 09:50-11:20

III-43Aziz Ouerdani

Concentration-QTc analysis versus Intersection Union Test: sample size considerations for a thorough QT study

Thursday 09:50-11:20

III-44Yaru Peng

Population pharmacokinetic meta-analysis and dosing recommendation of meropenem in critically ill patients receiving continuous renal replacement therapy

Thursday 09:50-11:20

III-45Amr Radwan

Design of a Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Children Aged 1-11 Years, With Active Eosinophilic Esophagitis

Thursday 09:50-11:20

III-46Juan Eduardo Resendiz Galvan

Population pharmacokinetics of moxifloxacin in Indian patients with multi-drug resistance tuberculosis

Thursday 09:50-11:20

III-47Federico Romano

Extrapolation of the early bacterial activity of pretomanid to inform dose selection for the treatment of pulmonary tuberculosis

Thursday 09:50-11:20

III-48Mohammed Saleh

Integration of the LeiCNS-PK3.0 PBPK framework and multiscale data to select anti-COVID19 drugs with favorable brain pharmacokinetics

Thursday 09:50-11:20

III-50Maria Luisa Sardu

Establishing correlates of protection for herpes zoster infection via MBMA analysis

Thursday 09:50-11:20

III-51Stef Schouwenburg

Oral versus intravenous amoxicillin in neonates: a population pharmacokinetic study

Thursday 09:50-11:20

III-52Gianluca Selvaggio

A QSP model to inform dose decision and fast track candidate lead in mRNA vaccines development

Thursday 09:50-11:20

III-53Jérémy Seurat

Rifampin co-administration with clindamycin can result in failure to reach the PKPD targets in staphylococcal osteoarticular infections

Thursday 09:50-11:20

III-54Eva Wehrhahn

A pharmacokinetic-pharmacodynamic model characterizing antibiotic-induced morphological changes in Pseudomonas aeruginosa from time-lapse microscopy images

Thursday 09:50-11:20

III-55Wisse van Os

Lefamulin exposure in soft tissues: population pharmacokinetics and pharmacokinetic/pharmacodynamic target attainment

Thursday 09:50-11:20

III-56Luka Verrest

Paromomycin population pharmacokinetic analysis in Eastern African visceral leishmaniasis patients

Thursday 09:50-11:20

III-57Umberto Villani

Probability of target attainment and dose optimisation of ceftriaxone in children and neonates

Thursday 09:50-11:20

III-58Ella Widigson

A pharmacometric evaluation of atypical plasma protein binding and probability of target attainment of tigecycline in obese and nonobese patients

Thursday 09:50-11:20

III-59Marie Wijk

Ethambutol population pharmacokinetics in South African patients with drug-susceptible tuberculosis

Thursday 09:50-11:20

III-60Tan Zhang

Vancomycin clearance in obese adults is not predictive of clearance in obese adolescents

Thursday 09:50-11:20

III-61Yuanxi Zou

Relative bioavailability of delamanid dispersed in water in healthy volunteers

Thursday 09:50-11:20